Despite the efforts made in the management of PDAC, the 5-year relative survival rate of pancreatic ductal adenocarcinoma (PDAC) still remains very low (10%). To date, precision oncology is far from being ready to be applied in cases of PDAC, although studies exploring the molecular and genetic alterations have been conducted, and the genomic landscape of PDAC has been characterized. This study aimed to apply a next-generation sequencing (NGS) laboratory-developed multigene panel to PDAC samples to find molecular alterations that could be associated with histopathological features and clinical outcomes. A total of 68 PDACs were characterized by using a laboratory-developed multigene NGS panel. KRAS and TP53 mutations were the more frequent alterations in 75.0% and 44.6% of cases, respectively. In the majority (58.7%) of specimens, more than one mutation was detected, mainly in KRAS and TP53 genes. KRAS mutation was significantly associated with a shorter time in tumor recurrence compared with KRAS wild-type tumors. Intriguingly, KRAS wild-type cases had a better short-term prognosis despite the lymph node status. In conclusion, our work highlights that the combination of KRAS mutation with the age of the patient and the lymph node status may help in predicting the outcome in PDAC patients.

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel / Malvi D.; Vasuri F.; Maloberti T.; Sanza V.; De Leo A.; Fornelli A.; Masetti M.; Benini C.; Lombardi R.; Offi M.F.; Di Marco M.; Ravaioli M.; Fiorino S.; Franceschi E.; Brandes A.A.; Jovine E.; D'errico A.; Tallini G.; de Biase D.. - In: DIAGNOSTICS. - ISSN 2075-4418. - ELETTRONICO. - 12:5(2022), pp. 1058.1058-1058.1068. [10.3390/diagnostics12051058]

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel

Malvi D.;Vasuri F.
Co-primo
;
Maloberti T.;De Leo A.;Offi M. F.;Di Marco M.;Ravaioli M.;Jovine E.;D'errico A.;Tallini G.;de Biase D.
2022

Abstract

Despite the efforts made in the management of PDAC, the 5-year relative survival rate of pancreatic ductal adenocarcinoma (PDAC) still remains very low (10%). To date, precision oncology is far from being ready to be applied in cases of PDAC, although studies exploring the molecular and genetic alterations have been conducted, and the genomic landscape of PDAC has been characterized. This study aimed to apply a next-generation sequencing (NGS) laboratory-developed multigene panel to PDAC samples to find molecular alterations that could be associated with histopathological features and clinical outcomes. A total of 68 PDACs were characterized by using a laboratory-developed multigene NGS panel. KRAS and TP53 mutations were the more frequent alterations in 75.0% and 44.6% of cases, respectively. In the majority (58.7%) of specimens, more than one mutation was detected, mainly in KRAS and TP53 genes. KRAS mutation was significantly associated with a shorter time in tumor recurrence compared with KRAS wild-type tumors. Intriguingly, KRAS wild-type cases had a better short-term prognosis despite the lymph node status. In conclusion, our work highlights that the combination of KRAS mutation with the age of the patient and the lymph node status may help in predicting the outcome in PDAC patients.
2022
Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel / Malvi D.; Vasuri F.; Maloberti T.; Sanza V.; De Leo A.; Fornelli A.; Masetti M.; Benini C.; Lombardi R.; Offi M.F.; Di Marco M.; Ravaioli M.; Fiorino S.; Franceschi E.; Brandes A.A.; Jovine E.; D'errico A.; Tallini G.; de Biase D.. - In: DIAGNOSTICS. - ISSN 2075-4418. - ELETTRONICO. - 12:5(2022), pp. 1058.1058-1058.1068. [10.3390/diagnostics12051058]
Malvi D.; Vasuri F.; Maloberti T.; Sanza V.; De Leo A.; Fornelli A.; Masetti M.; Benini C.; Lombardi R.; Offi M.F.; Di Marco M.; Ravaioli M.; Fiorino S.; Franceschi E.; Brandes A.A.; Jovine E.; D'errico A.; Tallini G.; de Biase D.
File in questo prodotto:
File Dimensione Formato  
diagnostics-12-01058.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.18 MB
Formato Adobe PDF
1.18 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/887306
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact